The Patent Finder

Kolon Tissuegene, Inc.

Also on record
Records under this name other than the patents Kolon Tissuegene, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 6 patents it holds.

Showing 1 to 6 of 6 · Back to Kolon Tissuegene, Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,431,922Bioadhesive directed somatic cell therapy
Term ended
Term ended Feb 27, 2024 · USPTO record
Term endedTerm ended Feb 27, 2024USPTO record
US 7,005,127Mixed-cell gene therapy
Term ended
Term ended Sep 25, 2023 · USPTO record
Term endedTerm ended Sep 25, 2023USPTO record
US 7,282,200Mixed-cell gene therapy
Term ended
Ended no later than Mar 5, 2023 · USPTO record
Term endedEnded no later than Mar 5, 2023USPTO record
US 6,315,992Generating cartilage in a mammal using fibroblasts transfected with a vector encoding TGF-.beta.-1
Term ended
Term ended Jun 30, 2019 · USPTO record
Term endedTerm ended Jun 30, 2019USPTO record
US 6,797,703Gene therapy using TGF-&bgr;
Term ended
Term ended Jun 30, 2019 · USPTO record
Term endedTerm ended Jun 30, 2019USPTO record
US 7,338,655Gene therapy using TGF-β
Term ended
Ended no later than Jun 30, 2019 · USPTO record
Term endedEnded no later than Jun 30, 2019USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited